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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the efficacy and safety of anti-interleukin-13 or anti-interleukin-4 agents, compared with placebo, anti-Immunoglobulin E
agents, or anti-interleukin-5 agents, for the treatment of children, adolescents, or adults with asthma.
B A C K G R O U N D
Description of the condition
Asthma is a prevalent, non-communicable, heterogeneous disease,
typically characterised by chronic airway inflammation (GINA
2017). Common symptoms include wheezing, chest tightness, a
cough, and shortness of breath, and are frequently worse early in
the morning or late at night (GINA 2017). Airflow limitation and
symptoms vary over time and in intensity, and are known to be
triggered by viral respiratory infections, changing weather, irritant
and allergen exposure, and exercise (GINA 2017). Symptoms and
airflow limitation can be absent for periods of weeks or months.
Asthma may affect up to 334 million individuals worldwide
(Global Asthma Network 2014), and has been highlighted as one
of the forum of international respiratory societies’ ’Big 5’ respira-
tory diseases (ERS 2017). It is noted as ’themost common chronic
condition in children, and is more severe in children in non-afflu-
ent countries’ (ERS 2017). Asthma is known to affect ’1 to 18% of
the population in different countries’ (GINA 2017), and can carry
a particularly serious burden in low- or middle-income countries,
which find it more difficult to afford the associated costs (Global
Asthma Network 2014).
The goal of asthma treatment is to maintain good activity lev-
els and control symptoms (GINA 2017). In addition, the use of
maintenance medication can reduce the future risk of exacerba-
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tions (GINA 2017). Individuals should also be assessed for any
relevant comorbidities (e.g. obstructive sleep apnoea, depression
and anxiety, obesity, rhinosinusitis, rhinitis, and gastroesophageal
reflux), which may contribute to asthma symptoms and poor con-
trol of asthma (GINA 2017).
It is increasingly accepted that asthma is a heterogeneous con-
dition, with distinct clinical phenotypes. One of the better
characterised phenotypes is that of eosinophilic asthma, where
eosinophils infiltrate the bronchial mucosa and airways, and cause
inflammation. Eosinophilic infiltration is a hallmark of both child-
hood-onset allergic asthma and late-onset non-allergic asthma. In
both cases, the cytokines interleukin-4, -5, and -13 play a central
role in the pathophysiology (de Groot 2015). Immunoglobulin
E (IgE) also plays a role, and treatment with anti-IgE therapies
can reduce airway and blood eosinophils, and associated inflam-
mation. However, some patients with uncontrolled eosinophilic
asthma do not respond to anti-IgE therapies, and continue to
exhibit eosinophilic inflammation. Therefore, therapies targeting
interleukin-4, -5, and -13, have been developed; the evidence
around anti-interleukin-5 therapies has recently been synthesised
elsewhere (de Groot 2015; Farne 2017).
Description of the intervention
The majority of anti-interleukin-13 and anti-interleukin-4 agents
are humanised monoclonal antibodies (i.e. biological therapies)
that bind to, and inhibit their respective inflammatory cytokines
or their receptors (Bice 2014; Kau 2014). Antibodies targeting the
interleukin-13 pathway alone include lebrikizumab, GSK67958,
tralokinumab, anrukinzumab, and IMA-026. Antibodies inhibit-
ing the interleukin-4 pathway alone include pascolizumab and
altrakincept. Antibodies inhibiting both the interleukin-4 and -
13 pathways include pitrakina, AMG-317, and dupilumab (Bice
2014; Kau 2014). All of the agents are administered by subcuta-
neous injection once every several weeks. However, pitrakina can
also be administered by nebulised inhalation.
How the intervention might work
Interleukins are a broad group of proteins, which are important in
cell signalling. Interleukin-13 is a pleiotropic cytokine produced
by type 2 helper T cells (TH ), and has been shown to drive
airway eosinophilia and increase airway inflammation in asthma.
Interleukin-13 contributes to goblet cell metaplasia, subepithelial
cell fibrosis, smooth muscle hyperplasia, and stimulation of pe-
riostin secretion (Woodruff 2007); periostin is a matricellular pro-
tein, which has a role in fibroblast activation and increasing col-
lagen gel elasticity (Sidhu 2010). These pathophysiological pro-
cesses are hallmarks of asthma. In preclinical models, interleukin-
13 has also been shown to increase airway hyper-responsiveness
(Chiba 2009). Interleukin-4 is a closely related cytokine, which
shares many of the biological and immunoregulatory functions
of interleukin-13 (Chomorat 1998). In particular, interleukin-4
plays an important role in maintaining the TH phenotype, lead-
ing to further secretion of interleukin-4 and -13 in a positive feed-
back effect (Bice 2014). Interleukin-4 also promotes B-cell isotype
switching, affects the production of chemokines by the airway ep-
ithelium, and increases IgE production (Li-Weber 2003).
Anti-interleukin-13 and -4 agents target these pathways with the
aim of reducing inflammation and airway remodelling, which are
both features of asthma. Furthermore, these agents may be more
effective in specific populations of people with asthma, such as
those with eosinophilic asthma, where inhibition of these path-
ways may reduce infiltration of eosinophils into the airways. It is
believed that blocking interleukin-13 may reduce very late anti-
gen-4 expression, and thus, reduce the movement of eosinophils
from circulation into airway tissue, and subsequently into the lu-
men (Pelaquini 2011). Glucorticosteroids have diverse effects on
the airways, including inhibition of interleukin-13 production;
however, some patients with poorly controlled asthma continue
to have elevated levels of interleukin-13, despite the use of high
dose inhaled or systemic glucocorticosteroids (Saha 2008). There-
fore, direct inhibition of interleukin-13 is a potential therapeutic
target in this group of patients, and agents, such as lebrikizumab,
have been shown to be effective in reducing interleukin-13 lev-
els following subcutaneous administration (Hanania 2016). Inhi-
bition of the interleukin-4 pathway by dupilumab has also been
shown to reduce levels of TH -associated inflammatory markers
in patients with persistent, moderate to severe asthma, following
the withdrawal of treatment with long-acting beta-adrenoceptor
agonists (LABA) and glucocorticoid therapy (Wenzel 2013).
Why it is important to do this review
Whilst severe or difficult to treat asthma represents only 5% to
10% of the total asthma population, these patients carry a dis-
proportionate burden of healthcare, socioeconomic, and personal
costs (Sullivan 2007). Around 1200 people die of asthma each
year in the UK, and approximately 40% of deaths occur in indi-
viduals with severe asthma (BLF 2012; RCoP 2014). Therefore,
it is imperative to find therapies that will offer improvements in
disease control for this group of patients.
It is important to synthesise the available evidence on the safety
and efficacy of anti-interleukin-13 and anti-interleukin-4 agents,
given that data from phase III clinical trials are becoming avail-
able (Hanania 2016). Whilst improvements in laboratory mark-
ers, such as forced expiratory volume in 1 second (FEV1; (Corren
2011)), and fraction of exhaled nitric oxide (FeNO; (Noonan
2013)) have been shown, a demonstration of consistent improve-
ment in patient symptoms appear to be more elusive (Corren
2011; de Boever 2014). Furthermore, some markers, such as el-
evated periostin levels, may identify a subset of patients who are
2Anti-interleukin-13 and anti-interleukin-4 agents versus placebo, anti-interleukin-5 or anti-immunoglobulin-E agents, for children and
adults with asthma (Protocol)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
more likely to have a favourable response. However, trial evidence
is again mixed in this respect.
O B J E C T I V E S
To assess the efficacy and safety of anti-interleukin-13 or anti-in-
terleukin-4 agents, compared with placebo, anti-Immunoglobulin
E agents, or anti-interleukin-5 agents, for the treatment of chil-
dren, adolescents, or adults with asthma.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised controlled trials (RCTs; parallel-
group). Cross-over trials will be excluded because the half-life of
these agents is in the order of a month, and thus trialists are un-
likely to implement a sufficient wash-out period for eliminating a
carry-over effect (i.e. several times the half-life). We will include
studies reported in full text, those published as an abstract only,
and unpublished data. We will exclude non-randomised studies.
Types of participants
Wewill include adolescents and adults (aged 16 years or older) and
children (younger than 16 years), with a diagnosis of asthma. We
will exclude participants with other chronic respiratory comor-
bidities (e.g. COPD, bronchiectasis). If a study includes a mixture
of patients with COPD and asthma, we will use or attempt to
obtain data for the subgroup of patients with asthma; if this is not
possible, the study will be excluded.
If studies in adolescent or adult populations include a proportion
of individuals under 16, and data are not reported separately, we
will include the study if the mean age in the intervention and
comparator groups is 16 years or older.
Types of interventions
We will include studies of adolescents and adults (aged 16 years or
older) and studies of children (younger than 16 years) in separate
comparisons. In each main comparison we will include studies
that compare the following:
1. Anti-interleukin-13 or -4 agents* with placebo.
2. Anti-interleukin-13 or -4 agents* with anti-
Immunoglobulin E (IgE) agents.
3. Anti-interleukin-13 or -4 agents* with anti-interleukin-5
agents.
*Some agents may inhibit both interleukin-13 and -4, and we will
also include studies of these agents.
We selected anti-interleukin-5 agents as active comparators, as
they target the initiation and maintenance of eosinophilic airway
inflammation (Ortega 2014). We selected anti-IgE agents as ac-
tive comparators, as they target IgE-mediated immune response,
thought to be involved in severe allergic asthma (Busse 2001).
We will include the following co-interventions, provided they are
not part of the randomised treatment: individuals’ usual short- or
long-acting medications (e.g. inhaled corticosteroids, long-acting
beta adrenoceptor agonists (LABA), long-acting muscarinic an-
tagonists (LAMA), leukotriene receptor antagonists).
If a study evaluates more than one dose of an anti-interleukin-13
or -4 agent (in separate arms), we will consider the most clinically
relevant dose. If the clinically relevant dose for a given agent is
not clear, we will extract data for both doses, and use the most
appropriate data set for the meta-analysis, based on the doses used
in the majority of other included studies.
Types of outcome measures
Primary outcomes
1. Exacerbations requiring hospitalisation or emergency
department visit (see section Unit of analysis issues for more
details)
2. Quality of life (measured on a validated asthma scale, e.g.
Asthma Quality of Life Questionnaire)
3. Serious adverse events (all causes)
Secondary outcomes
1. Exacerbations requiring oral corticosteroids
2. Lung function (e.g. change from baseline in forced
expiratory volume in 1 second (FEV1; (L)); change from baseline
in % predicted FEV1 (%); FEV1 bronchodilator reversibility
(%); concentration of methacholine needed to produce a 20%
fall in FEV1 from baseline (PC20 methacholine; (mg/mL)).
3. Asthma control (measured on a validated scale, e.g. Asthma
Control Questionnaire or Asthma Control Test)
4. Time off work or study
5. Adverse events (all causes)
6. Measures of airway inflammation (e.g. blood eosinophil
(count - absolute); sputum or bronchoalveolar lavage eosinophil
(%); fraction of exhaled nitric oxide (FeNO; (ppb)).
7. Reduction in oral corticosteroid dose.
We will extract data for each outcome at the time point closest
to the end of the treatment period. Where multiple outcomes
are proposed (i.e. as for lung function and measures of airway
inflammation), we will extract data for all available measures.
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Reporting one or more of the outcomes listed here in the study is
not an inclusion criterion for the review.
Search methods for identification of studies
Electronic searches
Wewill identify studies from theCochrane Airways Trials Register,
which is maintained by the Information Specialist for the Group.
The Cochrane Airways Trials Register contains studies identified
from several sources:
1. monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL), through the Cochrane Register
of Studies Online (crso.cochrane.org);
2. weekly searches of MEDLINE Ovid SP 1946 to date;
3. weekly searches of Embase Ovid SP 1974 to date;
4. Monthly searches of PsycINFO Ovid SP 1967 to date;
5. Monthly searches of CINAHL EBSCO (Cumulative Index
to Nursing and Allied Health Literature) 1937 to date;
6. Monthly searches of AMED EBSCO (Allied and
Complementary Medicine);
7. handsearches of the proceedings of major respiratory
conferences.
Studies contained in the Trials Register are identified through
search strategies based on the scope of Cochrane Airways. Details
of these strategies, as well as a list of handsearched conference pro-
ceedings are in Appendix 1. See Appendix 2 for search terms used
to identify studies for this review.
We will search the following trials registries:
1. US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov (www.clinicaltrials.gov)
2. World Health Organization International Clinical Trials
Registry Platform (apps.who.int/trialsearch)
Wewill search theCochrane Airways Trials Register and additional
sources from inception to present, with no restriction on language
of publication.
Searching other resources
We will check the reference lists of all selected studies for addi-
tional references. We will search relevant manufacturers’ websites
for study information.
We will search for errata or retractions from included studies pub-
lished in full text on PubMed, and report the date this was done
in the review.
Data collection and analysis
Selection of studies
Three review authors (DE, AG, ME) will independently screen
the titles and abstracts of the search results and code them as ’re-
trieve’ (eligible, potentially eligible, or unclear) or ’do not retrieve’.
We will retrieve the full-text study reports of all potentially el-
igible studies, and three review authors (DE, AV, ME) will in-
dependently screen them for inclusion, recording the reasons for
exclusion of ineligible studies. We will resolve any disagreement
through discussion, or if required, we will consult a fourth review
author (PM). We will identify and exclude duplicates and collate
multiple reports of the same study so that each study, rather than
each report, is the unit of interest in the review. We will record the
selection process in sufficient detail to complete a PRISMA flow
diagram and ’Characteristics of excluded studies’ table (Moher
2009).
Data extraction and management
We will use a data collection form for study characteristics and
outcome data, which has been piloted on at least one study in the
review. One review author (DS) will extract the following study
characteristics from included studies:
1. Methods: study design, total duration of study, details of
any ’run-in’ period, number of study centres and location, study
setting, withdrawals, and date of study.
2. Participants: N, mean age, age range, gender, severity of
condition, diagnostic criteria, baseline lung function, baseline
measures of airway inflammation, smoking history, inclusion
criteria, and exclusion criteria.
3. Interventions: intervention (including dose), comparison,
concomitant medications, and excluded medications.
4. Outcomes: primary and secondary outcomes specified and
collected, and time points reported.
5. Notes: funding for studies and notable conflicts of interest
of trial authors.
Three review authors (DE, AG, ME) will independently extract
outcome data from included studies. We will note in the ’Char-
acteristics of included studies’ table if outcome data were not re-
ported in a usable way.Wewill resolve disagreements by consensus,
or by involving a fourth review author (RS). One review author
(DE) will transfer data into the Review Manager 5 file (RevMan
2014). We will double-check that data are entered correctly by
comparing the data presented in the systematic review with the
study reports. A second review author (SD) will spot-check study
characteristics for accuracy against the study report.
Assessment of risk of bias in included studies
Three review authors (DE, AG,ME) will independently assess risk
of bias for each study, using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We will resolve any disagreements by discussion, or by involving
another author (PN/PM). We will assess the risk of bias according
to the following domains:
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1. random sequence generation;
2. allocation concealment;
3. blinding of participants and personnel;
4. blinding of outcome assessment;
5. incomplete outcome data;
6. selective outcome reporting;
7. other bias.
We will judge each potential source of bias as high, low, or un-
clear, and provide a quote from the study report together with a
justification for our judgement in the ’Risk of bias’ table. We will
summarise the ’Risk of bias’ judgements across different studies for
each of the domains listed.Wewill consider blinding separately for
different key outcomes where necessary (e.g. for unblinded out-
come assessment, risk of bias for all-cause mortality may be very
different than for a patient-reported pain scale). Where informa-
tion on risk of bias relates to unpublished data or correspondence
with a trialist, we will note this in the ’Risk of bias’ table.
When considering treatment effects, we will take into account the
risk of bias for the studies that contribute to that outcome.
Assessment of bias in conducting the systematic
review
We will conduct the review according to this published protocol
and justify any deviations from it in the ’Differences between
protocol and review’ section of the systematic review.
Measures of treatment effect
We will analyse dichotomous data as odds ratios (OR), and con-
tinuous data as risk ratios (RR), mean difference (MD), or stan-
dardised mean difference (SMD), which are presented with 95%
confidence intervals (CI). If data from rating scales are combined
in ameta-analysis, we will ensure they are entered with a consistent
direction of effect (e.g. lower scores always indicate improvement).
We will undertake meta-analyses only when this is meaningful;
that is, if the treatments, doses, participants, and the underlying
clinical question are similar enough for pooling to make sense.
We will describe skewed data narratively (for example, as medians
and interquartile ranges for each group).
Where multiple trial arms are reported in a single study, we will
include only the relevant arms. If two comparisons (e.g. drug A
versus placebo and drug B versus placebo) are combined in the
samemeta-analysis, wewill either combine the active arms or halve
the control group to avoid double-counting.
If adjusted analyses are available (ANOVA or ANCOVA), we will
use these as a preference in our meta-analyses. If both change from
baseline and endpoint scores are available for continuous data, we
will use change from baseline, unless there is a low correlation
between measurements in individuals. If a study reports outcomes
at multiple time points, we will use the latest available time point
(i.e. corresponding to end of study) for studies with a duration of
one year or less.
We will use intention-to-treat (ITT) or ’full analysis set’ analyses
when they are reported (i.e. when data have been imputed for
participants who were randomly assigned but did not complete
the study), instead of completer or per protocol analyses.
Unit of analysis issues
With the exception of outcomes relating to exacerbations, for di-
chotomous outcomes, we will use participants, rather than events,
as the unit of analysis (i.e. number of children admitted to hospi-
tal, rather than number of admissions per child). However, if data
were to permit the calculation of rate ratios, we will analyse them
on this basis. We would expect the majority of patients enrolled
in studies of anti-interleukin-13 and anti-interleukin-4 agents to
have relatively severe or uncontrolled asthma, and to experience at
least one exacerbation during the treatment period. Therefore, we
will synthesise data relating to exacerbations based on the number
of exacerbations per patient during the treatment period, using
rate ratios. We will only meta-analyse data from cluster-RCTs if
the available data have been adjusted (or can be adjusted), to ac-
count for the clustering.
Dealing with missing data
We will contact investigators or study sponsors to verify key study
characteristics and obtain missing numerical outcome data when
possible (e.g. when a study is identified as an abstract only). When
this is not possible, and the missing data are thought to introduce
serious bias, we will take this into consideration in the GRADE
rating for affected outcomes.
Assessment of heterogeneity
We will use the I² statistic to measure heterogeneity among the
studies in each analysis. If we identify substantial heterogeneity,
we will report it and explore the possible causes by our prespecified
subgroup analysis.
Assessment of reporting biases
If we are able to pool more than 10 studies, we will create and
examine a funnel plot to explore possible small study and publi-
cation biases.
Data synthesis
We will use a random-effects model to allow for differences in the
treatment effect from study to study, asmultiple types of treatment
will be grouped together. We will perform a sensitivity analysis
with a fixed-effect model. Rate ratios will be combined using the
generic inverse variance method.
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’Summary of findings’ table
We will create a ’Summary of findings’ table using the following
outcomes: exacerbations requiring hospitalisation or emergency
department visit, quality of life, serious adverse events (all causes),
exacerbations requiring oral corticosteroids, asthma control, time
off work or study, adverse events (all causes). We will use the five
considerations (risk of bias, consistency of effect, imprecision, in-
directness, and publication bias) to assess the quality of a body
of evidence as it relates to the studies that contribute data for the
prespecified outcomes. We will use the methods and recommen-
dations described in Section 8.5 and Chapter 12 of the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011),
using GRADEpro software (GRADEpro GDT). We will justify
all decisions to downgrade the quality of the evidence using foot-
notes, and we will make comments to aid the reader’s understand-
ing of the review where necessary.
Subgroup analysis and investigation of heterogeneity
We plan to carry out the following subgroup analyses for the pri-
mary outcomes (for each of the main comparisons in children,
and adolescents and adults, respectively):
1. Individual anti-interleukin-13 or anti-interleukin-4 agent
(e.g. including but not limited to lebrikizumab, tralokinumab,
IMA-026, GSK679586, anrukinzumab, pascolizumab,
pitrakina, altrakincept, AMG-317, dupilumab).
2. Agent class (anti-interleukin-13 only versus anti-
interleukin-4 only versus drugs that inhibit both interleukin-13
and -4 pathways).
3. Duration of therapy (up to 6 months versus longer than 6
months).
4. Severity of asthma as per Global Initiative for Asthma
(GINA) or British Thoracic Society/Scottish Intercollegiate
Guidelines Network (BTS/SIGN) definitions (mild or moderate
versus severe).
5. Category of TH inflammation (high versus low: e.g. as
determined by serum IgE concentration (high: ≥ 300 kU/L%),
exhaled nitric oxide (eNO; (high: ≥ 50 ppb)), airway eosinophil
count (high: sputum eosinophilia ≥ 3%), serum periostin (high:
≥ 50 ng/ml), or direct assay of serum or sputum IL-13 (high:
≥10 pg/mL)). Rationale: TH cells play a central role in
asthma; interleukin-4 controls the development of TH cells,
and interleukin-13 functions during the effector phase of
immunity, mediating the physiological response to TH -
induced inflammation. Patients with greater levels of TH
inflammation may respond better to anti-interleukin-13 or -4
therapies than patients with lower levels of TH inflammation.
6. Dose of corticosteroids (including prednisone), at
randomisation. Rationale: there is some overlap in the
mechanism of action between corticosteroids and anti-
interleukin agents; prior or concomitant corticosteroid use may
potentially confound the results, with greater effects of the anti-
interleukin agents observed when corticosteroid doses are low.
Equally, some patients may not respond to even high doses of
corticosteroids, but may respond to anti-interleukin-13 or -4
therapies.
We will use the formal test for subgroup interactions in Review
Manager 5 (RevMan 2014).
Sensitivity analysis
We plan to carry out the following sensitivity analyses, removing
the following from the primary outcome analyses:
1. Unpublished data.
2. Studies at high risk of bias for blinding of participants and
personnel.
3. Studies at high risk for random sequence generation or
allocation concealment.
We will compare the results from a fixed-effect model with the
random-effects model.
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A P P E N D I C E S
Appendix 1. Sources and search methods for the Cochrane Airways Trials Register (CAGR)
Electronic searches: core databases
Database Frequency of search
CENTRAL (the Cochrane Library) Monthly
MEDLINE Ovid Weekly
Embase Ovid Weekly
PsycINFO Ovid Monthly
CINAHL EBSCO Monthly
AMED EBSCO Monthly
Handsearches: core respiratory conference abstracts
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Conference Years searched
AmericanAcademyofAllergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Pacific Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards
MEDLINE search strategy used to identify trials for the CAGR
Asthma search
1. exp Asthma/
2. asthma$.mp.
3. (antiasthma$ or anti-asthma$).mp.
4. Respiratory Sounds/
5. wheez$.mp.
6. Bronchial Spasm/
7. bronchospas$.mp.
8. (bronch$ adj3 spasm$).mp.
9. bronchoconstrict$.mp.
10. exp Bronchoconstriction/
11. (bronch$ adj3 constrict$).mp.
12. Bronchial Hyperreactivity/
13. Respiratory Hypersensitivity/
14. ((bronchial$ or respiratory or airway$ or lung$) adj3 (hypersensitiv$ or hyperreactiv$ or allerg$ or insufficiency)).mp.
15. ((dust or mite$) adj3 (allerg$ or hypersensitiv$)).mp.
16. or/1-15
Filter to identify RCTs
1. exp “clinical trial [publication type]”/
2. (randomized or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
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8. or/1-7
9. Animals/
10. Humans/
11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and RCT filter are adapted to identify trials in other electronic databases.
Appendix 2. Search strategy to identify relevant studies from the Cochrane Airways Trials Register
1. AST:MISC1
2. MeSH DESCRIPTOR Asthma Explode All
3. asthma*:ti,ab
4. #1 or #2 or #3
5. Lebrikizumab:TI,AB,KW
6. MILR1444A
7. GSK679586
8. Tralokinumab:TI,AB,KW
9. CAT-354
10. Anrukinzumab:TI,AB,KW
11. IMA-638
12. IMA-026
13. Pascolizumab:ti,ab,kw
14. SB 240683
15. Altrakincept:ti,ab,kw
16. AMG-317
17. Dupilumab:ti,ab,kw
18. REGN668
19. pitrakinra:ti,ab,kw
20. aerovant:ti,ab,kw
21. AER 001
22. IL-13:ti,ab,kw
23 .anti-IL-13:ti,ab,kw
24. Interleukin 13:ti,ab,kw
25. anti-Interleukin-13:ti,ab,kw
26. IL-4:ti,ab,kw
27. anti-IL-4:ti,ab,kw
28. Interleukin 4:ti,ab,kw
29. anti-interleukin-4:ti,ab,kw
30. #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #
20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29
31. #30 AND #4
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